News
Get access to our breaking news, and company information
Press Releases
Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology
Study entitled “Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology” published in conjunction with the American Society of
Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants
– Laboratory and software validation testing determined ability to accurately identify key companion diagnostic targets within KRAS and EGFR genes, and specify associated approved therapy
Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel
NATICK, Mass. – March 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced the
Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
NATICK, Mass. – February 10, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that
Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory
NATICK, Mass. – January 6, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that
Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients
Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics, in response to emailed questions from MedCity